Cardio Diagnostics Holdings, Inc. Selling and Marketing Expense
Cardio Diagnostics Holdings, Inc. (CDIO) reported Selling and Marketing Expense of $190.18 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingAndMarketingExpense · last filed 2026-08-07
- Cardio Diagnostics Holdings, Inc. selling and marketing expense for the quarter ending 2026-06-30 was $190.18K, a 6.24% decline year-over-year.
- Cardio Diagnostics Holdings, Inc. selling and marketing expense for the quarter ending 2026-03-31 was $196.71K, a 4.09% increase year-over-year.
- Cardio Diagnostics Holdings, Inc. selling and marketing expense for the quarter ending 2025-06-30 was $202.85K, a 251.08% increase year-over-year.
- Cardio Diagnostics Holdings, Inc. selling and marketing expense for the quarter ending 2025-03-31 was $188.98K, a 449.32% increase year-over-year.
- Cardio Diagnostics Holdings, Inc. selling and marketing expense for fiscal 2025 was $766.89K, a 37.75% decline from fiscal 2024.
- Cardio Diagnostics Holdings, Inc. selling and marketing expense for fiscal 2024 was $1.23M, a 677.20% increase from fiscal 2023.
- Cardio Diagnostics Holdings, Inc. selling and marketing expense for fiscal 2023 was $158.51K, a 71.00% increase from fiscal 2022.
- Cardio Diagnostics Holdings, Inc. selling and marketing expense for fiscal 2022 was $92.70K, a 10.28% decline from fiscal 2021.
| Period end | Selling and Marketing Expense 3 month | Selling and Marketing Expense 3 month as first filed | Selling and Marketing Expense 6 month | Selling and Marketing Expense 9 month | Selling and Marketing Expense 12 month | Selling and Marketing Expense 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $190.18K 10-Q · filed 2026-08-07 | $386.89K 10-Q · filed 2026-08-07 | ||||
| 2026-03-31 | $196.71K 10-Q · filed 2026-05-15 | |||||
| 2025-12-31 | $766.89K 10-K · filed 2026-03-13 | |||||
| 2025-06-30 | $202.85K 10-Q · filed 2026-08-07 | $391.83K 10-Q · filed 2026-08-07 | $1.48M derived: sum of 3 quarters · filed 2026-08-07 | $1.53M derived: sum of 4 quarters · filed 2026-08-07 | ||
| 2025-03-31 | $188.98K 10-Q · filed 2026-05-15 | $41.82K 10-Q · filed 2025-05-15 | $1.28M derived: sum of 2 quarters · filed 2026-05-15 | $1.33M derived: sum of 3 quarters · filed 2026-05-15 | $1.39M derived: sum of 4 quarters · filed 2026-05-15 | |
| 2024-12-31 | $1.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $1.14M derived: sum of 2 quarters · filed 2026-03-13 | $1.20M derived: sum of 3 quarters · filed 2026-03-13 | $1.23M 10-K · filed 2026-03-13 | $182.45K 10-K · filed 2025-03-20 | |
| 2024-09-30 | $52.06K 10-Q · filed 2024-11-13 | $109.84K derived: sum of 2 quarters · filed 2024-11-13 | $144.24K 10-Q · filed 2024-11-13 | $187.53K derived: sum of 4 quarters · filed 2025-05-15 | ||
| 2024-06-30 | $57.78K 10-Q · filed 2024-08-12 | $92.18K 10-Q · filed 2024-08-12 | $135.47K derived: sum of 3 quarters · filed 2025-05-15 | $169.54K derived: sum of 4 quarters · filed 2025-05-15 | ||
| 2024-03-31 | $34.40K 10-Q · filed 2025-05-15 | $77.69K derived: sum of 2 quarters · filed 2025-05-15 | $111.76K derived: sum of 3 quarters · filed 2025-05-15 | $143.37K derived: sum of 4 quarters · filed 2025-05-15 | ||
| 2023-12-31 | $43.29K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $77.36K derived: sum of 2 quarters · filed 2025-03-20 | $108.96K derived: sum of 3 quarters · filed 2025-03-20 | $158.51K 10-K · filed 2025-03-20 | ||
| 2023-09-30 | $34.07K 10-Q · filed 2024-11-13 | $65.67K derived: sum of 2 quarters · filed 2024-11-13 | $115.23K 10-Q · filed 2024-11-13 | $142.35K derived: sum of 4 quarters · filed 2024-11-13 | ||
| 2023-06-30 | $31.61K 10-Q · filed 2024-08-12 | $81.16K 10-Q · filed 2024-08-12 | $108.29K derived: sum of 3 quarters · filed 2024-08-12 | $124.66K derived: sum of 4 quarters · filed 2024-08-12 | ||
| 2023-03-31 | $49.55K 10-Q · filed 2024-05-15 | $76.68K derived: sum of 2 quarters · filed 2024-05-15 | $93.05K derived: sum of 3 quarters · filed 2024-05-15 | $119.85K derived: sum of 4 quarters · filed 2024-05-15 | ||
| 2022-12-31 | $27.13K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $43.50K derived: sum of 2 quarters · filed 2024-04-01 | $70.30K derived: sum of 3 quarters · filed 2024-04-01 | $92.70K 10-K · filed 2024-04-01 | ||
| 2022-09-30 | $16.37K 10-Q · filed 2023-11-13 | $43.17K derived: sum of 2 quarters · filed 2023-11-13 | $65.57K 10-Q · filed 2023-11-13 | |||
| 2022-06-30 | $26.81K 10-Q · filed 2023-08-14 | $49.20K 10-Q · filed 2023-08-14 | ||||
| 2022-03-31 | $22.40K 10-Q · filed 2023-05-15 | |||||
| 2021-12-31 | $103.32K 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |